[Added CHEST 2008 study on Lovenox vs Arixtra. Please see MNTA ‘ReadMeFirst’ for info on M118.]
General #msg-25160571 Anticoagulant market has large potential (WSJ) #msg-26899903 Anticoagulant market has large potential (graphic) #msg-26451612 Venous thromboembolism is a big, big problem #msg-18759853 Overview of the new oral anticoagulants #msg-26701803 Technical overview of traditional anticoagulants
Apixaban #msg-31742223 Apixaban fails vs Lovenox in phase-3 #msg-32024540 Tepid phase-2 results in ACS #msg-19134406 PFE, BMY ink $1B collaboration #msg-29928836 Seventh and eighth phase-3 trials begin #msg-21044973 Apixaban non-inferior to Warfarin in phase-2
Pradaxa (dabigatran) #msg-32382343 NICE approves Pradaxa in only six months #msg-27956748 EU approves Pradaxa for VTE prevention #msg-26086079 BI completes enrollment of huge AF trial #msg-25152872 BI starts phase-2 in ACS #msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention
Lovenox #msg-26739674 US market share #msg-28936334 Where Lovenox sales come from #msg-33630772 Lovenox not more costly than Arixtra (CHEST 2008) #msg-11669012 Lovenox more economical than unfractionated heparin
Miscellaneous (in alphabetical order) #msg-29601951 Ablynx ALX-0081 begins phase-1b in PCI #msg-10569101 Arixtra bests Lovenox in ACS #msg-27043616 ART-123 from Artisan Pharma #msg-33309473 ARYX ATI-5923: A safer warfarin? #msg-22938795 AVE5026 and otamixaban (SR123781 dropped Feb08) #msg-31161411 AZD0837 comes out of the closet #msg-26298260 Biotinylated idraparinux causes excess bleeding #msg-31950663 Daiichi Sankyo phase-2 data for DU-176b #msg-30965016 LLY terminates FXa program #msg-30353872 MYGN MPC-0920 begins phase-1 #msg-31461171 NUVO reports phase-1b data for NU172 #msg-27187973 Paion’s Solulin completes phase-1 #msg-28742653 Paion acquires flovagatran rights #msg-32171800 Regado reports phase-1 data for aptamer
Market Data 
Markets 
AI
